New drug combo aims to stop deadly lung Cancer's return
NCT ID NCT07431827
Summary
This study is testing whether adding a new targeted drug (MK-1084) to an existing immunotherapy helps prevent lung cancer from coming back after surgery. It involves 400 people with a specific genetic mutation (KRAS G12C) whose lung cancer was surgically removed. The main goal is to see if this combination keeps patients cancer-free longer compared to standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.